ovarian

Constructing Directional cDNA Libraries from Limited Amounts of RNA

... cloning PCR products. We usedthe kit to create an ovarian cancer cDNA library from tissue isolated bylaser-c... Fig.1 Ovarian Tumor Library An ovarian tumor library was made from approximately 100 ng of total RNA derived from LCM tissue. cDNA ...

Isolate High Quality Total RNA from LCM Samples Suitable for Microarray and qRT-PCR Analysis

...d were also observed when isolating total RNA from ovarian tumor LCM samples using a combination of A...) was 80.4 5.6 (n=8). (B) RNA was isolated from ovarian tumor LCM samples (100 laser shots per sample) using Ambion's LCM Stains (Acridine O...

Perform RNAi Library Screens on Any Budget

...arcinoma), UMR106 (rat osteosarcoma), SKOv3 (human ovarian carcinoma), and SKNAS (human bone marrow neuroblastoma) cells. Plate-to-Plate, Well-to-Well, and Lot-to-Lot Consistency in Performance A good transfec...

Protect RNA and Improve Target Cell Identification

...M System (Arcturus). LCM sample Cluster of ovarian adenocarcinoma cells. Acridine Orange (Fluorescent Intercalating Stain) Acridine Orange stain intercalates into nucleic acids to enhance visability of nuclei in clusters of cells (Figure 3...

Extended data analysis using DeCyder EDA

...vanced statistics on samples from a study on human ovarian cancer. The known samples could be clearly separat...data set was a BVA workspace from a study on human ovarian cancer. All samples were classified by pathologists into one of the following three groups: normal, ...

SNPs Powerful Tools for Association Studies

...et al. 1994. A strong candidate for the breast and ovarian cancer gene BRCA1. Science. 266, 66-71. Rioux, J.D., et al. 2000. Genome wide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. Am. J. Hum. Genet. June; 66 (6):1863-70. Rioux, J.D., et ...

ESR1 Gene Expression in Oncology and Metabolic Diseases Using the ASCENTATM System Target Validation and Identification of Novel Disease Indications

...d to a lesser yet significant level in the SK-OV-3 ovarian cancer cell line. ESR1 expression was not detected in several prostate, lung and colonderived cell lines. The specificity and extent of expression regulation of a gene target with respect to human disease is another important metric th...

Protein Depletion for Plasma and Serum Proteomic Analysis

...Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359 :572-577. <... of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005, 5 :4589-4596. </LI> <LI >Kozak KR, Amneus MW, P...

A Screen of shRNAs Targeting Tumor Suppressor Genes to Identify Factors Involved in Paclitaxel Sensitivity

... BRCA1 has been found to be mutated in breast and ovarian tumors, and patients with these mutations can be more responsive to chemotherapies than patients with this gene intact. Patients with renal cell carcinoma and a mutation or truncation in the VHL tumor suppressor gene have better response rates an...

The Genesis of Gendicine: The Story Behind the First Gene Therapy

...cancer, breast cancer, cervical cancer, and ovarian cancer. Although Gendicine has not been formally approved by SFDA for indications other than HNSCC, terminal patients with no other avenue of treatment have been allowed, on a case-by-case basis, to receive Gendicin...

NeoClone gets $750K for ovarian cancer detection

Madison, Wis. - Of all the forms of cancer, ovarian cancer is one of the most difficult to detect in ...tinue research into biological markers that signal ovarian cancer, according to a report in the Wisconsin State Journal . The grant was awarded by the Nati...

Quintessence cancer treatment chosen for clinical studies

...man pancreatic, non-small cell lung, prostate, and ovarian tumors. Of the 30 EVade ribonucleases that Quintessence has tested, QBI-139 had the broadest efficacy in multiple tumor lines. QBI-139 is the first of some very exciting compounds identified in our drug development efforts, Ralph Kauten, presiden...

The Coming of Biotech Generic Pharmaceuticals

...ed the drug and focused its initial development in ovarian cancer and subsequently other types of cancer to a point where annual sales reached $1.6 billion before the Taxol patent expired. The NCI recouped very little back from Bristol-Myers Squibb for all its early work. M&A Activity Helps Drive 2003 B...